• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Wilson Perrin Megan

    6/23/25 4:15:07 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLYM alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Wilson Perrin Megan

    (Last) (First) (Middle)
    C/O CLIMB BIO, INC.
    20 WILLIAM STREET, SUITE 145

    (Street)
    WELLESLEY HILLS MA 02481

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    06/17/2025
    3. Issuer Name and Ticker or Trading Symbol
    Climb Bio, Inc. [ CLYM ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Business Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) (1) 02/09/2035 Common Stock 600,000 $1.58 D
    Explanation of Responses:
    1. The option was granted on February 10, 2025 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through February 10, 2029, subject to the Reporting Person's continued service.
    Remarks:
    Exhibit Index: 24.1 - Power of Attorney
    /s/ Chandra Adams, as Attorney-in-Fact 06/23/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CLYM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CLYM

    DatePrice TargetRatingAnalyst
    6/6/2025$10.00Outperform
    Oppenheimer
    5/22/2025$7.00Buy
    BTIG Research
    12/2/2024$10.00Outperform
    Leerink Partners
    More analyst ratings

    $CLYM
    SEC Filings

    See more
    • SEC Form 8-K filed by Climb Bio Inc.

      8-K - Climb Bio, Inc. (0001768446) (Filer)

      6/18/25 7:08:36 AM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Climb Bio Inc.

      8-K - Climb Bio, Inc. (0001768446) (Filer)

      6/5/25 4:05:36 PM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Climb Bio Inc.

      DEFA14A - Climb Bio, Inc. (0001768446) (Filer)

      5/23/25 4:32:18 PM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLYM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Climb Bio with a new price target

      Oppenheimer initiated coverage of Climb Bio with a rating of Outperform and set a new price target of $10.00

      6/6/25 8:35:04 AM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Climb Bio with a new price target

      BTIG Research initiated coverage of Climb Bio with a rating of Buy and set a new price target of $7.00

      5/22/25 8:24:05 AM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Climb Bio with a new price target

      Leerink Partners initiated coverage of Climb Bio with a rating of Outperform and set a new price target of $10.00

      12/2/24 9:55:08 AM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLYM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer

      Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll, MBA, Financial Executive with Over Two Decades of Experience Guiding Biotechnology Companies, as Senior Vice President, Finance WELLESLEY HILLS, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced the appointments of Edgar D. Charles, M.D., MSc as its Chief Medical Officer (CMO) and Cindy J. Driscoll, MBA as Senior Vice President, Finance. "The expansi

      6/18/25 7:00:00 AM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      WELLESLEY HILLS, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that the Company has granted an inducement equity award to a new employee, pursuant to the Company's 2025 Inducement Plan, as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity award was granted to one new employee on May 19, 2025, and consisted of a non-statutory stock option to purchase up to an aggregate of 120,000 shares of common stock of the Company. The option has an ex

      5/19/25 4:34:52 PM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

      Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE) on Track to Initiate in 2025 CLYM116 Progressing Towards Anticipated IND or CTA Submission in Second Half 2025 Appointed Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors and Perrin Wilson, Ph.D., as Chief Business Officer Strong Financial Position, with Cash Runway Expected Through 2027 WELLESLEY HILLS, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the first quarte

      5/14/25 7:00:00 AM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLYM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Brennan Aoife converted options into 68,750 shares and sold $25,154 worth of shares (20,618 units at $1.22) (SEC Form 4)

      4 - Climb Bio, Inc. (0001768446) (Issuer)

      7/1/25 4:37:17 PM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Thomas Stephen Basil converted options into 25,094 shares, increasing direct ownership by 14% to 204,282 units (SEC Form 4)

      4 - Climb Bio, Inc. (0001768446) (Issuer)

      7/1/25 4:32:24 PM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Wilson Perrin Megan

      3 - Climb Bio, Inc. (0001768446) (Issuer)

      6/23/25 4:15:07 PM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLYM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Climb Bio Inc.

      SC 13G/A - Climb Bio, Inc. (0001768446) (Subject)

      11/14/24 9:29:34 AM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLYM
    Leadership Updates

    Live Leadership Updates

    See more
    • Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer

      Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll, MBA, Financial Executive with Over Two Decades of Experience Guiding Biotechnology Companies, as Senior Vice President, Finance WELLESLEY HILLS, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced the appointments of Edgar D. Charles, M.D., MSc as its Chief Medical Officer (CMO) and Cindy J. Driscoll, MBA as Senior Vice President, Finance. "The expansi

      6/18/25 7:00:00 AM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

      WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

      4/1/25 7:00:00 AM ET
      $ABOS
      $CLYM
      $LENZ
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer

      WELLESLEY HILLS, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) announced today the appointment of Perrin Wilson, Ph.D. as Chief Business Officer. Dr. Wilson is an accomplished leader, with over 17 years of experience in the pharmaceutical and biotech industry. "I am delighted to welcome Dr. Perrin Wilson to the Climb Bio management team," said Aoife Brennan, President and CEO of Climb Bio. "Perrin brings extensive experience and a track record of success across large pharma and biotech to Climb Bio. As Chief Business Officer, she will lead the Company's pre-commercial planning, communications, and business development efforts. Perrin's proven expertise in negotiat

      2/24/25 7:00:00 AM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care